NEW YORK, Oct. 16, 2013 /PRNewswire-iReach/ -- NEW YORK, NY (October 16, 2013) Reproductive Medicine Associates of New York (RMA of New York), a Manhattan-based infertility clinic, in conjunction with Celmatix Inc., a New York City-based biotech firm, announced today their significant research progress toward the identification of novel genetic markers that may aid in the understanding of unexplained female infertility. The findings from their study, "Whole Genome Sequencing for Female Infertility Biomarker Discovery," were presented in a poster session at the 2013 annual meeting of the American Society for Reproductive Medicine (ASRM), taking place October 12th through the 17th in Boston, Massachusetts.

"Given recent advances in fertility preservation technologies such as egg freezing, there is great value in discovering biomarkers to identify women who are at risk for infertility," said Alan Copperman, MD, a study co-author and founding partner of RMA of New York. "Ultimately, personalized genetic markers like those identified in this study will give physicians the ability to rapidly diagnose female infertility, streamline fertility treatments, and better and more efficiently help patients achieve reproductive success."

RMA of New York and Celmatix have partnered to discover genetic biomarkers that could be predictive of infertility and to make better use of the clinical data that is gathered through various trials and research. Focusing on the 'FertilomeTMDNA', the region of the human genome that Celmatix analyses have shown is most likely to encode a woman's fertility potential, the researchers identified potential biomarkers for idiopathic (unexplained) female infertility and premature decline in ovarian reserve and function.

"As additional areas of medicine move toward precise treatment recommendations based on a patient's unique genetic make up, we are excited to be partnered with Dr. Copperman and his colleagues at RMA of New York to make this dream a reality for women suffering from infertility," states Piraye Yurttas Beim, Ph.D., Founder and Chief Executive Officer of Celmatix. "To our knowledge, these are the first whole genome datasets that have been generated of women experiencing unexplained infertility and primary ovarian insufficiency."

More than seven million women in the United States are affected by infertility. Of these women, over 10 percent have infertility of indeterminate causes. Diagnostic assays based on genomic sequencing will assist physicians in the identification of previously unexplained causes of infertility and in the determination of viable candidates for egg donation, aiding individuals and couples in the family planning process.

The authors of the study were Piraye Yurttas Beim, Ph.D.; Tina Hu-Seliger, Ph.D.; Michael Elashoff, Ph.D.; Rebecca Chodroff, Ph.D.; Joseph Lee, B.A.; and Alan B. Copperman, M.D.

About Reproductive Medicine Associates of New York

Reproductive Medicine Associates of New York (RMA of New York) is widely recognized as a national and international leader in state-of-the-art reproductive medicine. Led by an integrated team of doctors and scientists with extensive reproductive endocrinology, fertility and urology experience and training, RMA of New York consistently reports IVF success rates to the Society for Assisted Reproductive Technology (SART) and the Center for Disease Control and Prevention (CDC) and is internationally recognized for achieving high success rates in the treatment of infertility. RMA of New York maximizes access to care by helping patients explore all insurance coverage and financing options available for treatment. RMA of New York is sensitive to the needs of the LGBT community, women choosing single or same-sex motherhood, as well as women interested in elective fertility preservation. Headquartered in midtown Manhattan, RMA of New York has patient care facilities in Garden City, White Plains, Brooklyn and Cornwall, NY. For more information, please visitwww.rmany.com.

About Celmatix Inc.

Founded in 2009, Celmatix is a New York City-based biotechnology company focused on helping women overcome infertility by identifying underlying genetic causes for the condition and developing tools and technologies to help optimize treatment outcomes. Celmatix has identified the regions of the human genome that are most likely to influence a woman's fertility potential and are now mining novel genetic biomarkers for different infertility disorders in these regions. Celmatix has also developed the first data analytic models that can predict the cumulative probability of success across the entire fertility treatment journey for a given couple. For more information, visit http://www.celmatix.com.

Go here to see the original:
Reproductive Medicine Associates of New York and Celmatix Announce Significant Research Strides Toward Identifying ...

Comments are closed.